Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes
Authors' conclusion
Patients with Type 2 diabetes who initiate SGLT2i and experience a UTI or GTI within the following year have an elevated frequency of subsequent SGLT2i discontinuation.
Study context
- Population
- New SGLT2i users with T2D, Denmark, 2016–2021SGLT2i initiators
- Participants
- 68,277 users
- Exposure
- SGLT2i users with vs without incident urinary tract infection (UTI) or genital tract infection (GTI)
- UTIn = 5,892
- GTIn = 1,389
- Outcome
- SGLT2i discontinuation: no new prescription filled within 60 days after previous supply ended
- Follow-up
- Date of first expected SGLT2i refill
Methodological detailsmatched 1:3 by sex, age, treatment duration and calendar year, new-user design
- Matched 1:3 by sex, age, treatment duration and calendar year
- New-user design
Main finding
As reported in the abstract
SGLT2i discontinuation · date of first expected refill
UTI vs No UTI
Estimate (95% CI)
Excess risk
7.6%(6.4%–8.8%)
GTI vs No GTI
Estimate (95% CI)
Excess risk
2.2%(−0.1% to 4.5%)
Observational data: associations, not effects.
Further findings
SGLT2i discontinuation · 1 year
| Outcome | UTI | No UTI | GTI | No GTI |
|---|---|---|---|---|
| Incidence of UTI and GTI within 1 year of SGLT2i initiation · first year | 8.6% | — not stated in the abstract | 2% | — not stated in the abstract |
— not stated in the abstract
Original publication
Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes. Diabetes Obes Metab. Published 14 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →